Loading stock data…
TLPH
$0.82-0.03 (-3.68%)
After Hours$0.82+0.00 (+0.00%)· Last close Jun 9
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Talphera, Inc. in the Healthcare sector is trading at $0.81 with a market capitalization of $40M. Wall Street consensus targets $3.17 (3 analysts), implying a +290.9% move over the next 12 months. The stock is currently 48% below its 52-week high of $1.57, remaining 15.6% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +290.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$0.82
Potential Downside
0%
Whystock Fair Value$0.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that a...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$40.22M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-118.40%
Volume
Today's trading volume
170,757
Recent News
Talphera, Inc. Q1 2026 Earnings Call Summary
Moby summary of Talphera, Inc.'s Q1 2026 earnings call
Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...
Talphera Inc (TLPH) reports significant advancements in its NEFRO study, while managing increased operating costs and strategic enrollment updates.
Talphera Q1 2026 Earnings Call Transcript
Talphera (NASDAQ:TLPH) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to our entire catalog, please visit https://www.benzinga.com/apis/ for a consultation. The full earnings call is available at https://app.webinar.net/8B95lMZwZmO Summary Talphera Inc has made significant progress in their Nefro CRRT study, surpassing the 50% enr
Talphera (TLPH) Q1 2026 Earnings Transcript
With this continued progress, we believe we are well positioned to complete enrollment in the nephro CRRT study this year. As mentioned, in early March, we announced the attainment of the 50% enrollment milestone in the nephro study.
Talphera: Q4 Earnings Snapshot
SAN MATEO, Calif. AP) — Talphera, Inc. TLPH) on Monday reported a loss of $3.8 million in its fourth quarter.